A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.
Wittman
Brenda
B
Department of Pediatric Hematology/Oncology, Golisano Children's Hospital at Strong, University of Rochester Medial Center, Box 777, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Horan
John
J
Baxter
Joanna
J
Goldberg
John
J
Felgar
Raymond
R
Baylor
Erin
E
Cromwell
Bean
B
Cross
Nicholas
N
Bennett
John M
JM
D001549:Benzamides; D002675:Child, Preschool; D002881:Chromosomes, Human, Pair 12; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014178:Translocation, Genetic; D020797:Receptor, Platelet-Derived Growth Factor beta; D000097764:ETS Translocation Variant 6 Protein
D001549:Benzamides; D000068877:Imatinib Mesylate; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; C464679:ETV6-PDGFRB fusion protein, human; D020797:Receptor, Platelet-Derived Growth Factor beta; D000097764:ETS Translocation Variant 6 Protein